The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels

PHASE2RecruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

October 29, 2025

Study Completion Date

December 30, 2025

Conditions
Cadmium Exceeds the Standard
Interventions
DRUG

GMDTC for injection

GMDTC for Injection with a specification of 0.5g/vial, and administered by intravenous infusion. According to the drug preparation SOP , Using 0.9% physiological saline to achieve the required concentration for each dose group (e.g., The initial dose group: 2 g reconstituted in 500 mL, with each 1 g reconstituted in 250 mL, resulting in a 4 mg/mL concentration.). All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.

OTHER

0.9% Sodium Chloride Injection(0.9% NaCl)

0.9% Sodium Chloride Injection with a specification of 250mL/bag, and administered by intravenous infusion. The infusion should be strictly adhering to the assigned dosage. All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.

Trial Locations (1)

510300

RECRUITING

Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment, Guangzhou

All Listed Sponsors
collaborator

Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment

UNKNOWN

lead

Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.

OTHER

NCT07057414 - The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels | Biotech Hunter | Biotech Hunter